15-03-2013

Both daughters and sons from divorced families are significantly more likely to initiate smoking in comparison to their peers from intact families, shows a new analysis of 19,000 Americans. This University of Toronto study, published online this month in the journal Public Health, shows that ...

more

Companies to Collaborate on Central Nervous System Disorder Opportunity

06-01-2012

Ironwood Pharmaceuticals, Inc. and Bionomics Limited announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics’ investigational anti‐anxiety compound BNC210 and other related compounds. The goal of the ...

more

BNC210 significantly reduced panic symptoms and faster than placebo

31-03-2011

Bionomics Limited has successfully concluded two Phase Ib clinical trials of BNC210 which is being developed as a new generation treatment for anxiety and depression. The two trials of BNC210 were initiated in France in October 2010 following approval by the French Medical Agency AFSSAPS ...

more

New entity will be based in Radebeul, Germany

09-11-2010

biocrea GmbH announced further details about the newly incorporated company and its strategy going forward. biocrea acquires the CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform from Biotie Therapies Corp. The new company will be based in Radebeul, Germany. Dr. Thomas ...

more

First trial will evaluate the potential for BNC210 to relieve panic attacks and reduce symptoms of anxiety

06-10-2010

Bionomics Limited announced approval from the French Medical Agency AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante) and the Ethics Committee of the Strasbourg Hospital, CPP (Comité de Protection des Personnes), to perform two advanced Phase I clinical trials with ...

more

26-08-2010

Addex Pharmaceuticals Ltd announced that the Phase I studies required to commence Phase II testing of ADX71149 have been satisfactorily completed. Subject to regulatory authorizations, Phase IIa studies in schizophrenia and anxiety, are scheduled to start enrolling patients in the first ...

more

16-08-2010

The names of the finalists in this year’s European Biotechnica Award have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round. Addex Pharmaceuticals, based in Plan-Les-Ouates ...

more

Effect is comparable to potent psychotropic drugs

19-07-2010

Instead of a sleeping pill or a mood enhancer, a nose full of jasmine from Gardenia jasminoides could also help: in collaboration with Dr. Olga Sergeeva and Prof. Helmut Hass from the Heinrich Heine University in Düsseldorf, researchers from Bochum led by Prof. Dr. Dr. Dr. Hanns Hatt have ...

more

30-06-2010

PharmaNeuroBoost NV (PNB) reported that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for PNB01. PNB01 is a proprietary owned, fixed dose combination of citalopram and low dose pipamperone, and is under development for the treatment of ...

more

22-06-2010

Bionomics Limited announced it has completed its second Phase I clinical trial of its anti-anxiety compound BNC210. The aim of this trial was to determine whether administration of BNC210 with food alters blood levels of the drug. Dr Deborah Rathjen Bionomics’ CEO & Managing Director ...

more